Novel transfection reagent set to alleviate viral vector bottleneck
The FectoVIR-AAV transfection reagent achieves large-scale transient transfection resulting in up to a 10-fold increase in AAV functional viral titer yields in suspension cell systems.
Polyplus-transfection, a biotechnology company that supplies the gene and cell therapy market with innovative transfection solutions, will make available to the market a novel transfection reagent FectoVIR-AAV in May 2020.
The reagent has been specifically developed to improve AAV (adeno-associated virus) production in suspension cell culture system for large-scale manufacturing.
AAVs are predominantly used in gene therapy development. To date, there has been a significant and well-identified bottleneck in manufacturing sufficient amounts of AAV viral vectors to treat patients. This will continue to increase as more therapies are commercialized and reach late-stage clinical trials.
To increase capabilities, viral manufacturers are looking for effective ways to adapt key steps of production for large-scale manufacturing. Transient transfection is a critical step that is indispensable for a reliable industrial manufacturing process. Polyplus-transfection has developed the FectoVIR-AAV transfection reagent to achieve large-scale transient transfection resulting in up to a 10-fold increase in AAV functional viral titer yields in suspension cell systems.
Polyplus-transfection developed the FectoVIR-AAV transfection reagent in partnership with a range of viral manufacturers internationally. Rather than follow the industry standard model of developing a reagent for small-scale manufacturing and adapting for large-scale production, Polyplus-transfection has developed the entirely new reagent with large-scale transient transfection in mind, and then validated its use all the way through the R&D process.
“The AAV viral vector bottleneck has been persistently identified as a major challenge for the development of the entire gene therapy industry,” said Karsten Wilking, CEO, Polyplus-transfection. Yet, by working with a range of handpicked international viral manufacturers to provide the FectoVIR-AAV reagent, the company has helped to alleviate a major concern for the gene therapy sector and will result in a high number of therapies reaching the market and patients more quickly.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance